Bain Capital leads $215m Series D funding in Atea Pharmaceuticals, which is developing a covid-19 drug

Other investors in the funding included RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, T. Rowe Price, Redmile Group and Omega Funds. Existing investors are also participating, including Morningside Ventures, Cormorant Asset Management, Ally Bridge Group and Sectoral Asset Management.

DealsHealthcareBriefs